Repligen (RGEN) Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RGEN shares.
View RGEN analyst ratings or view top-rated stocks.

9 brokers have issued 12-month price objectives for Repligen's shares. Their RGEN share price forecasts range from $165.00 to $240.00. On average, they expect the company's stock price to reach $199.00 in the next twelve months. This suggests a possible upside of 24.1% from the stock's current price.
View analysts price targets for RGEN or view top-rated stocks among Wall Street analysts.

Repligen's stock was trading at $169.31 at the beginning of the year. Since then, RGEN stock has decreased by 5.3% and is now trading at $160.31.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our RGEN earnings forecast.

Repligen Co. (NASDAQ:RGEN) announced its earnings results on Wednesday, August, 2nd. The biotechnology company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.04. The biotechnology company earned $159.20 million during the quarter, compared to analyst estimates of $165.93 million. Repligen had a net margin of 18.92% and a trailing twelve-month return on equity of 7.83%. Repligen's revenue for the quarter was down 23.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.91 EPS.

ETFs with the largest weight of Repligen (NASDAQ:RGEN) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Invesco Biotechnology & Genome ETF (PBE), BlackRock Future Innovators ETF (BFTR), Fidelity Disruptive Medicine ETF (FMED), VanEck Biotech ETF (BBH), Nuveen ESG Mid-Cap Growth ETF (NUMG), BNY Mellon Innovators ETF (BKIV) and Invesco ESG NASDAQ Next Gen 100 ETF (QQJG).

Repligen issued an update on its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided EPS guidance of $1.72-$1.80 for the period, compared to the consensus earnings per share estimate of $2.29. The company issued revenue guidance of $635.00 million-$665.00 million, compared to the consensus revenue estimate of $721.07 million.

13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Repligen's stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (2.96%), Sands Capital Management LLC (2.86%), Brown Capital Management LLC (2.59%), Artisan Partners Limited Partnership (2.51%), Bank of New York Mellon Corp (1.90%) and Impax Asset Management Group plc (1.82%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Martin D Madaus, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends.

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RGEN stock can currently be purchased for approximately $160.31.

Repligen (NASDAQ:RGEN) has a market capitalization of $8.94 billion and generates $801.54 million in revenue each year. The biotechnology company earns $185.96 million in net income (profit) each year or $2.42 on an earnings per share basis.

The company employs 2,025 workers across the globe.

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The official website for the company is www.repligen.com. The biotechnology company can be reached via phone at (781) 250-0111, via email at investors@repligen.com, or via fax at 781-250-0115.